Abstract 1066
Background
Ostomy patients (pts) can develop some complications treated by nurse enterostomista, such as skin alterations and early or late complications. Stomal complications have a varying incidence (from 25 to 35%). Neoplastic ostomy pts often undergo chemo (CT) and/or radiation therapy (RT), also in association, and they can show stomal lesions or complications with an important impact on their daily life. Stomal side effects induced by CT-RT represent an important problem for pts, who need for a competent and organized support in order to be able to cope with them. In the literature, few studies report the care and assistance to the stomized pts.The aim of this study was to detect precociously stomal complications in order to treat them early, improving pts quality of life, and to demonstrate that these complications are more frequent in pts treated with CT and/or RT.
Methods
From 11.2017 to 5.2018 60 cancer ostomy pts were surgically treated for different types of cancers at our institution. 29 out 60 have been also treated with CT and/or RT at Medical Oncology Dept. 73% were male and 27% female. We evaluated stomal complications and classified them according to SACS scale. Our aim was to demonstrate a higher percentage of stomal complications in pts CT and/or RT treated vs untreated pts.
Results
At a median follow-up of 4 months, 29 out 60 ostomy pts were treated with CT, 2 with CT-RT, the remaining 29 underwent follow-up. 15 out 29 pts (51%) treated with CT and/or RT showed stomal complications: 14 with SACS - L1 skin alterations (redness without loss of substance) and 1 with SACS-L2 lesion (with loss of substance). Patients undergoing follow-up didn’t have any stomal complications.
Conclusions
Despite the recognized limitations of our study (small sample size and short median follow-up) we can conclude that there is an increase of complications in ostomy pts treated with CT and/or RT vs untreated pts and that this problem occurs in over half of population.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Cristoforo Ferrero.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3842 - Effect of docetaxel-resistance on the reactivity of prostate cancer cells to metformin
Presenter: Jessica Catapano
Session: Poster Display session 3
Resources:
Abstract
5198 - Cell plasticity and taxanes resistance in metastatic prostate cancer: ESRP1 as a predictive biomarker of taxane response
Presenter: Natalia Jimenez
Session: Poster Display session 3
Resources:
Abstract
2981 - Effect of Selumetinib plus AZD8186 treatment on Cabazitaxel sensitivity in docetaxel-acquired resistant metastatic prostate cancer cell lines
Presenter: Vicenc Ruiz de Porras
Session: Poster Display session 3
Resources:
Abstract
2779 - Anti-tumor activity of cediranib, a pan-inhibitor of vascular endothelial growth factor receptors, in pancreatic ductal adenocarcinoma cells
Presenter: Majid Momeny
Session: Poster Display session 3
Resources:
Abstract
1782 - The molecular mechanisms of EpCAM in regulating tumor progression and development of anti-EpCAM antibodies for colon cancer diagnosis and therapy
Presenter: Han-chung Wu
Session: Poster Display session 3
Resources:
Abstract
1322 - Detection of microRNAs as biomarker for anti-EGFR antibody resistance in colon cancer patients
Presenter: Jens Hahne
Session: Poster Display session 3
Resources:
Abstract
1579 - Serum exosomal microRNA-199b-5p as a novel circulating biomarker to predict response of preoperative chemoradiotherapy for locally advanced rectal cancer
Presenter: Dong Won Baek
Session: Poster Display session 3
Resources:
Abstract
1761 - Live biobank of patient-derived organoids from Thai colorectal cancer patients enables clinical outcome prediction
Presenter: Pariyada Tanjak
Session: Poster Display session 3
Resources:
Abstract
3542 - The biological implications of PDCD6 dysregulation in colorectal cancer
Presenter: Romina Briffa
Session: Poster Display session 3
Resources:
Abstract
4634 - Comparative molecular analyses between microsatellite stable BRAFV600E mutant colorectal cancers and BRAFV600E mutant melanomas.
Presenter: Mohamed Salem
Session: Poster Display session 3
Resources:
Abstract